All posts tagged: Future Medicine

The Relationship between Cannabis and Schizophrenia

July 3, 2019 Abuse, Addiction, Anxiety, Behavior change, Cannabinoids, Cannabis, Cannabis Education, Cannabis Science, Cognition, DSM-5, Future Medicine, Psychosis, Schizophrenia, Science, Stigma, Stress

Cannabis and Psychosis: Are We any Closer to Understanding the Relationship?

Despite the constant technological gains in medicine, there is still insufficient information and knowledge about who is at risk of developing cannabis psychosis prior to an individual’s exposure to cannabis. Controlled research is limited due to the legal status of cannabis but the growing number of states legalizing medicinal and recreational use of cannabis will likely provide a naturalistic experiment that will produce a prevention strategy for the condition. Current schizophrenia research is limited to western male populations and an overemphasis on the biological model; future research should extend to a more diverse population and sociocultural factors that may lead to schizophrenia.

View this review (yellow link) or download:

Cannabis and Psychosis- Are We any Closer to Understanding the Relationship?Download

This paper is also stored here: http://bit.ly/2FcDVJR inside the CED Foundation Archive

To explore related information, click the keywords below:

80%: Cannabis extremely helpful for pain; 82%: helped reduce or stop over-the-counter medications; 88% able to stop taking opioid painkillers

July 2, 2019 Anti-inflammatory properties, Arthritis, Cannabinoids, Cannabis, Cannabis Science, Case Study, CBD, Fibromyalgia, Future Medicine, Insomnia, Muscle Pain, Neuropathy, Opiates, Pain, Science, Sleep, THC

“The study, published in the Journal of Psychoactive Drugs, which looked at 1,000 people taking legalized marijuana in an American state found that among the 65% of people taking cannabis for pain, 80% found it was very or extremely helpful.”

“82% of these people being able to reduce, or stop taking over the counter pain medications, and 88% being able to stop taking opioid painkillers.”

“74% of the 1,000 interviewees bought it to help them sleep – 84% of whom said the marijuana had helped them, and over 83% said that they had since reduced or stopped taking over-the-counter or prescription sleep aids.”

“The study adds weight to the theory that widening access to medical cannabis could lower the use of prescription painkillers, allowing more people to manage and treat their pain without relying on opioid prescription drugs that have dangerous side effects.”

“This is backed up with other research that shows that states with medical cannabis laws have a 6.38% lower rate of opioid prescribing and that Colorado’s adult-use cannabis law is associated with a relative reduction in opioid overdose death rate from 1999 to 2010.”

“”Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen cause GI bleeding or kidney damage with chronic use. Paracetemol (Acetaminophen) toxicity is the second most common cause of liver transplantation worldwide, and is responsible for 56,000 ER visits, 2600 hospitalizations, and 500 deaths per year in the U.S.”

Link to news brief: https://eurekalert.org/pub_releases/2019-07/tfg-cmb062819.php

View this review (yellow link) or download:

This paper is also stored here: http://bit.ly/2JmB7Lv inside the CED Foundation Archive

To explore related information, click the keywords below:

Video: Cannabinoid Intervention for PTSD: Where to Next?

July 2, 2019 Anxiety, Behavior change, Cannabinoids, Cannabis, Cannabis Education, Cannabis Science, CBD, Depression, Future Medicine, Insomnia, Memory, PTSD, Sleep, Stigma, THC, Veterans

The endocannabinoid system has long been recognized as a promising target for PTSD treatment.

Here, a 2018 literature review summarizes the risks and benefits of cannabis as a treatment option. Watch our video adaptation, and review the source literature, below:

View this review (yellow link) or download:

Cannabinoid interventions for PTSD: Where to next?Download

This paper is also stored here: http://bit.ly/2XgnrXn inside the CED Foundation Archive

To explore related information, click the keywords below:

Cannabinoids in the treatment of cancer

July 2, 2019 Anti-inflammatory properties, Cancer, Cannabinoids, Cannabis, Cannabis Education, Cannabis Science, Colon Cancer, Dermatology / Skin, Future Medicine, Ovarian Cancer, Prostate Cancer, Science

A literature review from 2009 (10 years ago) summarizes the anti-cancer properties of cannabis, concluding that various cannabinoids might inhibit cancer cell growth and tumor growth. In particular, cannabis shows promise to help treat colon, skin, prostate, and breast cancer.

Cannabinoids-in-the-treatment-of-cancer Download

This paper is also stored here: http://bit.ly/2J1XS8A inside the CED Foundation Archive

To explore related information, click the keywords below:

Patients are Unclear on Cannabis Dosing

July 2, 2019 Cannabinoids, Cannabis, Cannabis Education, Cannabis News, CB1, CB2, CBD, Dosing, Epilepsy, Future Medicine, Products, THC

Dr. Ernest found that 82% of her epileptic patients found cannabis treatment helpful, but she also found that many of them were unaware of the doses they were taking or the levels of THC and CBD. Doctors and patients alike need to learn about dosing to maximize their health benefits http://bit.ly/2J29kkB

To explore related information, click the keywords below:

Cannabidiol Treatment for Parkinson’s Disease

July 1, 2019 Aging, Anti-inflammatory properties, Anxiety, Arthritis, Autoimmunity, Behavior change, Cannabinoids, Cannabis, Cannabis Education, Cannabis Science, CB1, CB2, CBD, Depression, DSM-5, Elderly, Future Medicine, Insomnia, Memory, Muscle Pain, Neuropathy, Parkinson's Disease, Science

Cannabidiol: a hope to treat non‑motor symptoms of Parkinson’s Disease Patients

Cannabidiol (CBD) has recently been postulated as an ideal drug to address the treatment of non-motor symptoms of Parkinson’s Disease (PD) due to its multifaceted mechanism of action. The plethora of effects of CBD includes anti-inflammatory, neuroprotective, anxiolytic, and antipsychotic actions, which improve non-motor symptoms of PD and lift the quality of life for patients coping with the illness. Further research is recommended to garner support for FDA approval.

View this review (yellow link) or download:

Cannabidiol: A hope to treat non‑motor symptoms of Parkinson’s disease patients Download

This paper is also stored here: http://bit.ly/2KXTb0Y inside the CED Foundation Archive

To explore related information, click the keywords below:

Study Reveals that Flavanoids can act as Allergy Medications

June 29, 2019 Aging, Allergy, Anti-inflammatory properties, Autoimmunity, Blood-Levels, Extraction, Flavonoids, Future Medicine, Non-Cannabis Plant, Oral Health, Placebo-Controlled, Science, Terpenes

Anti-histaminic Effects of Resveratrol and Silymarin on Human Gingival Fibroblasts

It has recently been revealed that the flavonoids resveratrol and silymarin have an anti-histaminic effect on human gingival fibroblasts (HGF). HGF are cells that compose part of the gum tissue in the oral cavity. Silymarin and resveratrol were already known to have anti-bacterial and anti-inflammatory properties, but a recently published study has now revealed that silymarin alone and a combination of the two flavonoids both provide novel therapeutic approaches for inflammation due to allergies.

View this review (yellow link) or download:

Anti-histaminic Effects of Resveratrol and Silymarin on Human Gingival Fibroblasts Download

This paper is also stored here: http://bit.ly/2Ff1lhW inside the CED Foundation Archive

To explore related information, click the keywords below:

Israel and the global cannabis market

June 28, 2019 Business of Cannabis, Cannabis, Cannabis News, Future Medicine, History, Israel, Jobs, Processing, Products

Some believe that it is difficult to compete with industry giants, such as Tilray and Cronos. But, Israel’s long history of cannabis research and its innovative companies, leading tech and strong agricultural climate make it a likely region to attract many in the global cannabis market. http://bit.ly/2IPXbz8

To explore related information, click the keywords below:

Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study

June 28, 2019 Adverse Effects, Canada, Cannabis Education, Cannabis Science, Driving, Future Medicine, History, Legislation, Reaction Time, Regulation, Social Justice, Stigma

Title of study: Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study

After legalization in 2018, many Canadian provinces implemented “zero tolerance” policies for drivers who have THC in their systems. But a new study from the University of British Columbia suggests that Canada’s drug-impaired driving laws may be unnecessarily strict. According to researchers, there is no link between THC levels below 5ng/mL and increased risk of car accidents.

Note: Considering the potentially grave risk to life and health for modern culture to make the wrong interpretation of the potential dangers of the effects of cannabis consumption on driving, it is critical for the industry to approach the circumstances with delicacy and diligence. Ideally, everyone involved will be motivated to learn as much as possible about the impact of cannabis on the risks of operating machinery and all will follow a cautious approach which will minimize the risk to all. To that end, it is important to consider and reconcile evidence from multiple perspectives.

The article:

“New study suggests low levels of THC in blood do not increase risk of car crash” https://www.straight.com/cannabis/1256476/new-study-suggests-low-levels-thc-blood-do-not-increase-risk-car-crash#

View this review (yellow link) or download:

Cannabis use as a risk factor for causing motor vehicle crashes- a prospective study Download

This paper is also stored here: http://bit.ly/2IVhSJY inside the CED Foundation Archive

To explore related information, click the keywords below:

The Cannabinoid System is a Promising Source of Targets for Treating Pain

June 28, 2019 Addiction, Adverse Effects, Anti-inflammatory properties, Anxiety, Arthritis, Autoimmunity, Blood-Levels, Cannabinoids, Cannabis, Cannabis Science, CB1, CB2, CBD, Citizen Science, Cognition, Elderly, Future Medicine, Memory, Multiple Sclerosis, Muscle Pain, Neuropathy, Occasional Use, Opiates, Overdose, Pain, Placebo-Controlled, Products, Regulation, Science, Stigma, Stress, THC

A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain ECS

The cannabinoid system provides momentum to develop cannabinoid-based medications to treat inflammatory and neuropathic pain as researchers continue to find promising therapeutic targets. These new targets may lead to the formation of novel pain-relief medications that may serve well to alleviate pain for those suffering from cancer, multiple sclerosis, and fibromyalgia. Cannabis-based pain medicine is also being researched for opioid-sparing effects and effectiveness in reducing the necessary dose of opioids.

View this review (yellow link) or download:

A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain ECS Download

This paper is also stored here: http://bit.ly/2FfLorA inside the CED Foundation Archive

To explore related information, click the keywords below: